Latest Headlines

31. RoosterBio And Qkine Partner To Deliver A Single-Source Platform Of Cells, Media, And Growth Factors To U.S. Customers 7/7/2026

    RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins.

32. CCRM At 15: Powering Canada's Rise In Cell And Gene Therapy 7/1/2026

    CCRM is proud to celebrate its 15th anniversary, marking a decade and a half of advancing regenerative medicine and helping to establish Canada as a global player in the maturing cell and gene therapy field.

33. Rinn Advanced Therapies And CCRM Explore Establishment Of CCRM Ireland 6/29/2026

    Rinn Advanced Therapies, Ireland’s national research centre for personalized immune cell therapies, today announced the signing of a Memorandum of Understanding (MOU) with CCRM, a global leader in cell and gene therapy development and commercialization. The agreement outlines a strategic collaboration to explore establishing a CCRM-affiliated advanced therapies hub in Ireland.

34. Proliant Health & Biologicals Raises The Albumin Standard With AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin 6/24/2026

    Proliant Health & Biologicals announces the commercial launch of AlbufreeDX, a recombinant human albumin (rHA) designed to meet the growing demand for high-performance, animal-free ingredients across diagnostic and life science applications.

35. Asimov Launches Chrysalis Transposase, A Wholly-Owned Genome Integration Tool For Biotherapeutics Production 6/23/2026

    Asimov announces Chrysalis transposase, a proprietary genome integration tool engineered to deliver higher titers, greater expression stability, and faster cell recovery than conventional transposases.

36. Avance Clinical Announces Asia Pacific And Mainland China Expansion Ahead Of BIO International Convention 2026 6/23/2026

    Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.

37. The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing 6/18/2026

    The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

38. Minaris Enhances GMP Cell Banking Suites At Philadelphia Facility 6/18/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. 

39. Leica Biosystems And CellCarta Expand Collaborative Companion Diagnostic Development Model To Accelerate Commercialization Globally 6/1/2026
40. Andelyn Biosciences Establishes The Andelyn Foundation To Support Families Living With Rare And Ultra-Rare Diseases 5/29/2026

    Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit organization dedicated to supporting families living with rare and ultra-rare diseases through awareness, fundraising, and compassionate community engagement.